about bpl

Bio Products Laboratory Ltd.

News

PRESS RELEASE - Gammaplex® Approved For Use in Pediatric Patients

Gammaplex © Approved For Use In Pediatric Patients Gammaplex [Immune Globulin Intravenous (Human) 5% Liquid] Approved in Patients 2 years and Older with  Primary Immunodeficiencies ELSTREE, UK AND DURHAM, NC - August 6, 2015 - Bio Products Laboratory Limited (BPL), a leading manufacturer of plasma-derived protein ...

Date added: Thursday 6th August 2015
Latest updated: Wednesday 8th February 2017

FDA Accepts BPL’s Amended BLA Submission for Coagadex® (Coagulation Factor X, Human)

ELSTREE, UK AND DURHAM, NC - May 27, 2015 – Bio Products Laboratory, Ltd. (BPL), a leading manufacturer of plasma-derived therapies, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s amended Biologics License Application for Coagadex® for hereditary ...

Date added: Friday 29th May 2015
Latest updated: Wednesday 8th February 2017

PRESS RELEASE - Bio Products Laboratory, Ltd. Announces Results from Phase III Registration Study of its Factor X Coagulation Product

ELSTREE, UK AND DURHAM, NC - April 17, 2015 - Bio Products Laboratory, Ltd. (BPL), a leading manufacturer of plasma-derived protein therapies, today announced the results from a phase III registration study examining the pharmacokinetics, efficacy, and safety of its FACTOR X coagulation product in ...

Date added: Monday 27th April 2015
Latest updated: Wednesday 8th February 2017

Patient information leaflets